Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Epix Goes Bust
by Lisa M. Jarvis
July 27, 2009
| A version of this story appeared in
Volume 87, Issue 30
With only enough cash on hand to make it through August and no investors or partners in sight, Lexington, Mass.-based Epix Pharmaceuticals is throwing in the towel. The company has fired nearly all its employees and is in the process of liquidating its assets to pay off creditors. Epix had an in silico drug discovery platform that allowed it to make models of intra- and extracellular domains of a protein, which could then be used to screen small molecules as potential drug candidates. The company had collaborations with GlaxoSmithKline, Amgen, and the Cystic Fibrosis Foundation.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter